The pro-apoptosis effects of *Echinacea purpurea* and *Cannabis sativa* extracts in human lung cancer cells through caspase-dependent pathway

Fatemeh Hosami1, Azadeh Manayi2, Vahid Salimi3, Farshad Khodakhah3, Mitra Nourbakhsh1, Britt Nakstad4,5 and Masoumeh Tavakoli-Yaraki1*

**Abstract**

**Background:** Considering the advantages of using medicinal herbs as supplementary treatments to sensitize conventional anti-cancer drugs, studying functional mechanisms and regulatory effects of *Echinacea purpurea* (as a non-cannabinoid plant) and *Cannabis sativa* (as a cannabinoid plant) are timely and required. The potential effects of such herbs on lung cancer cell growth, apoptosis, cell cycle distribution, cellular reactive oxygen species (ROS) level, caspase activity and their cannabinomimetic properties on the CB2 receptor are addressed in the current study.

**Methods:** The cytotoxic effect of both herb extracts on the growth of lung cancer cells (A549) was assessed using the MTT assay. The annexin-V-FITC staining and propidium iodide (PI) staining methods were applied for the detection of apoptosis and cell cycle distribution using flow cytometry. The cellular level of ROS was measured using 7′-dichlorofluorescin diacetate (DCFH-DA) as a fluorescent probe in flow cytometry. The caspase 3 activity was assessed using a colorimetric assay Kit.

**Results:** *Echinacea purpurea* (EP) root extract induced a considerable decrease in A549 viable cells, showing a time and dose-dependent response. The cell toxicity of EP was accompanied by induction of early apoptosis and cell accumulation at the sub G1 phase of the cell cycle. The elevation of cellular ROS level and caspase 3 activity indicate ROS-induced caspase-dependent apoptosis following the treatment of A549 cells by EP extract. The observed effects of EP extract on A549 growth and death were abrogated following blockage of CB2 using AM630, a specific antagonist of the CB2 receptor. Increasing concentrations of *Cannabis sativa* (CS) induced A549 cell death in a time-dependent manner, followed by induction of early apoptosis, cell cycle arrest at sub G1 phase, elevation of ROS level, and activation of caspase 3. The CB2 blockage caused attenuation of CS effects on A549 cell death which revealed consistency with the effects of EP extract on A549 cells.

(Continued on next page)

* Correspondence: tavakoli.m@iums.ac.ir; masoumeh.tavakoli@gmail.com
1Department of Biochemistry, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
Full list of author information is available at the end of the article

© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background

The endocannabinoid system (ECS) is an extensive lipid signaling complex system that is involved in regulating numerous physiological mechanisms and pathological processes in the human body [1]. This system consists of cannabinoid receptors, eicosanoid compounds called endogenous cannabinoids or endocannabinoids, and enzymes that synthesize and break down these compounds [2]. The cannabinoid receptors, members of the rhodopsin-like G-protein coupled receptor (GPCR) family, mediate the biological effects of cannabinoids. Cannabinoids are terpenoid lipid-based chemicals isolated from Cannabis sativa (Marijuana) which has been proven to exert its effects by specific binding to cannabinoid receptors [3]. Both cannabinoid receptors and naturally occurring cannabinoids, known as phytocannabinoids, have potential therapeutic applications based on their pivotal roles in regulating immunologic responses, alleviating inflammation, tumor cell proliferation, angiogenesis, invasion, and migration [4–7].

Related to this, current antitumor agents and cytotoxic drugs are not sufficiently effective due to aberrant signal transduction and resistance in lung cancer cells. Therefore, the development of new complementary agents for the treatment of lung cancer patients is needed and necessary [8].

Interestingly, it was shown that the cannabinoid receptor 2 (CB2) was overexpressed in patients with non-small cell lung cancer (NSCLC) and tumor growth and lung metastasis was remarkably inhibited by CB2 agonists [9]. Also, it was revealed that activation of CB2 by JWH-133 inhibits epithelial to mesenchymal progression, which leads to suppression of tumor growth in NSCLC [10]. Another study [11] found that JWH-015, a CB2 agonist, could inhibit EGFR (Epidermal growth factor receptor), FAK (Focal adhesion kinase), VCAM1 (Vascular cell adhesion protein 1), and MMP2 (Matrix metallopeptidases2) pathways and prevent the accumulation of tumor-associated macrophages (TAMs) and control NSCLC lung cancer cells invasion. Also, drug-therapeutic compounds, including cannabinoids, can be transferred to lung cancer cells by inhalation with minimal side effects, using high-energy electron-dispersing nanoparticles, to induce cell death [12]. Recent studies have shown that cannabis derivatives suppress epidermal growth factor (EGF) and its downstream pathways in human lung cancer cells that cause blockage of tumor cell proliferation and migration [13]. Moreover, Echinacea purpurea (EP), known as coneflower, belongs to the Asteraceae family and exerts immune-modulation, anti-inflammatory, anti-mutagenicity, anti-bacterial, anti-viral, larvicidal, and psychoactivity features [14]. EP can prevent virus-induced bacterial adhesion to epithelial cells and reduce the risk of respiratory inflammation and infection [15, 16]. EP modulates cytokine secretion and attenuates the clinical symptoms in mice infected by influenza [17]. Moreover, EP-isolated polysaccharides modulate the anti-tumor activity of cyclophosphamide that may be induced in mice transplanted with lung carcinoma [18]. Effects of EP can be attributed to alkaloids, the major constituent of EP that have similar characteristics as cannabinoids [19, 20]. Due to this structural similarity, alkaloids mimic cannabinoids and bind to cannabinoid receptors, especially CB2, then subsequently trigger the same pathways and immunologic reactions as cannabinoids do [2, 21]. Both EP root and Cannabis sativa, an ancient medicinal plant that contains phytocannabinoids, may play a crucial role in the pathophysiology of lung cancer, but the effects of these herbals on cancer cell growth and mechanisms of death have not been adequately addressed. In this study, we aimed to investigate the impacts of EP root and Cannabis sativa (CS) flower ethanolic extracts, on A549 lung cancer cells. We clarify and compare their possible effects on cell viability, rate of apoptosis, cell cycle distribution, level of ROS and caspase 3 activities. The CB2 antagonist AM630 was applied to delineate whether the observed effects happened in a CB2- dependent manner.

Methods

Chemicals and reagents

DMEM (Dulbecco’s Modified Eagle Medium) high glucose, trypsin/EDTA, NaCl/Pi, penicillin, and streptomycin were obtained from Gibco (Rockville, USA). The annexin-V-fluorescein isothiocyanate (annexin-V-FITC) apoptosis detection kit, propidium iodide (PI), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), dimethyl sulfoxide (DMSO) was purchased from Sigma Aldrich (Munich, Germany). The caspase 3 colorimetric assay kit was obtained from Bio Vision (CA,
USA). Fluorescent Reactive Oxygen Species (ROS) detection kit was obtained from Marker Gene Technologies (MGT, USA). The 6-iodopravadoline (AM630) was purchased from Tocris (Bristol, UK).

**EP and CS extracts preparation**

The extracts of *Echinacea purpurea* (EP) root and *Cannabis sativa* (CS) female flower was prepared by the Medicinal Plants Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. The specimens were identified by Dr. Gholam Reza Amin and deposited at the herbarium of the of Faculty of Pharmacy, Tehran University of Medical Sciences (*Cannabis sativa*: pmp-1378 and *Echinacea purpurea*: pmp-1222). Briefly, 100 g of EP roots and the flowering part of female CS flower, respectively and separately, were crushed and extracted using a maceration method (3 × 48 h). Dichloromethane was used to extract EP root and aqueous methanol (80%) applied for extraction of CS female flowers. The obtained extracts were concentrated and freeze dried to powders and kept at 4 °C until examination.

**Cell culture**

The human lung cancer cell line A549 and the human normal lung fibroblast-like cell line, MRC-5 were obtained from the Pasteur Institute of Iran. A549 Cells were cultured and nourished in a DMEM high glucose media supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin solution (Pen-Strep), while EMEM media supplemented with 10% fetal bovine serum (FBS) was applied for MRC-5 cell culture. Cells were maintained at 37 °C in 5% CO2 and 100% humidity. At the confluence of 70–90%, cells were collected by trypsination and the collected cells were either used freshly, or frozen and stored at −80 °C for subsequent experiments. Cells were seeded in 96-well plates with a density of 20,000 cells per well and incubated overnight, then the medium was replaced with fresh medium containing EP and CS extracts and different concentrations and CB2 antagonist, and AM-630 for further assays.

**Cell viability assay (MTT assay)**

The cytotoxic effect of CS and EP extracts, and the agonistic effect of AM630 (6-iodopravadoline) on A549 cells were assessed using MTT colorimetric assay. Briefly, cells were cultured in 96-well plate with the density of 20,000 cells/well in DMEM high glucose, supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin solution, in 5% CO2 at 37 °C. After being confluent, cells were treated with different concentrations of CS (50–900 ng/ mL) or EP (50–900 ng/ mL), respectively, and incubated for 24, 36 or 48 h. AM630 is a proven selective antagonist of CB2 receptor [22], so cells were co-treated with AM630 in a dose-dependent manner (10, 25, 50 nM) to clarify its possible effect on A549 viability. Further, we studied the effect of AM630 on the CB2 receptor, in the presence of EP or CS, respectively. Following incubation of A549 with the various extracts and/or agonist present, 20 mg/mL of 5 mg/ mL MTT solved in PBS was added to each well and incubated for an extra 4 h at 37 °C. The drug-containing medium along with MTT was then removed and replaced with a 200 mg/ mL of DMSO, which dissolved the formazan crystals and changed the color of the solution from colorless/yellow to purple. After 15 min, the plates were read with a microplate reader (Bio-Rad, CA, USA) at 570 nm and the data regarding the viability of the cells in each well was reported as the absorbance percentage of treated cells via control cells. The experiment was repeated several times and data are representative of at least three independent experiments and values are expressed in mean ± standard deviation (SD). The IC50 values were measured for EP and/or CS at each time point for both A549 and MRC-5 cells using nonlinear regression of transformed data. To determine the selectivity index (SI) which is the criterion indicating the degree of cytotoxic selectivity and specificity of compound for cancer cells against normal cells, the IC50 of EP (50–900 ng/ mL) and/or CS (50–900 ng/ mL) extracts calculated for MRC-5 cells divided by IC50 of A549 cells at each time point. The SI values more than 2 is considered as high selectivity [23].

**Apoptosis assessment**

The annexin-V-FITC kit was applied to quantify the percentages of apoptotic cells using flow cytometry. Briefly, A549 cells were treated with (100, 300, or 500 ng/ mL) of CS and EP extracts, respectively, in the presence or absence of AM630 (50 nM), then harvested and washed by PBS. The cell pellets were suspended in 500 µL of 1 × binding buffer, 5 µL of annexin-V-FITC, and 5 µL of PI and incubated for 10 min at room temperature. Further, samples were transferred to FACSCalibur flow cytometry (Becton Dickinson, San Jose, USA) tube and analyzed using the supplied software in the instrument.

**Cell cycle analysis**

The propidium iodide (PI) staining was applied to analyze the DNA content and cell cycle distribution using flow cytometry. Cells were treated with CS (100 or 300 ng/ mL) or EP (100 or 300 ng/ mL) with and without AM630 (50 nM) for 36 h and fixed with 70% (v/v) ice-cold ethanol and washed twice with ice-cold PBS. The pellets were stained with 0.1 mg/ mL RNase A (Sigma, Munich, Germany) and 0.05 mg/ mL PI and incubated in the dark, 37 °C for 1 h. The percentages of cells in each phase of the cell cycle were determined by
the FACSCalibur flow cytometer (Becton Dickinson, SanJose, USA) and the inbuilt software (BD Cell Quest software). The accumulation of cells in the subG1 phase of the cell cycle is considered as the hallmark of apoptosis.

**Measurement of intracellular reactive oxygen species (ROS)**

The amount of cellular ROS is associated with the incidence of apoptosis, thus the level of ROS following treatment of cells with CS extract (100 or 300 ng/ mL) or EP (100 or 300 ng/ mL), both with and without AM630 (50 nM) for 36 h, was measured. The 2′,7′-dichlorofluorescin diacetate (DCFH-DA) as a fluorescent probe was applied for the detection of ROS level. DCFH-DA (20 μM working substrate solution) was added to the cells and incubated at 37 °C for 45 min before treatment. The level of generated fluorescence was correlated to the amount of produced ROS that was detected by FACS Calibur flow cytometer (Becton Dickinson, SanJose, USA).

**Measurement of caspase 3 activity**

The level of caspase 3 activity was detected using the caspase 3 colorimetric assay kit (Bio Vision, CA, USA). Cells were treated with CS (100 or 300 ng/mL) or EP (100 or 300 ng/mL) in the presence or absence of AM630 (50 nM) for 36 h. The cell pellets were lysed by a cold lysis buffer and incubated for 15 min. The reaction buffer (50 μM) contained 10 mM dithiothreitol (DTT) and 5 μM of DEVD conjugated to p-nitroaniline (DEVDPNA) substrate (200 μM) and was added to each sample and incubated for 120 min at 37 °C. The caspase 3 activity was measured at emission wavelength 405 using a microplate reader.

**Statistical analysis**

The data analysis and statistical calculations were performed by Graph Pad Prism version 6 (Graph Pad Software, San Diego, California). The non-parametric one-way analysis of variance (ANOVA) with Dennet’s and Tukey’s post hoc test was used to determine differences between groups. For determining specificity and accuracy, all experiments were implemented in triplicate and repeated at least three times. Data are presented as mean ± standard deviation (SD) and differences were taken significant for \( P < 0.05 \), \( P < 0.01 \), and \( P < 0.001 \). Statistical differences between different groups in each graph are marked with an asterisk. The number of asterisks indicate the degree of statistical difference and shown as * \( P < 0.05 \), ** \( P < 0.01 \), *** \( P < 0.001 \), **** \( P < 0.0001 \) in the corresponding figures.

**Results**

**EP extract induced the time and dose-dependent cell death in A549 cells**

To determine the possible effect of EP extract on human lung cancer cell growth, A549 cells were incubated with EP extract (50–900 ng/mL) for 24, 36, and 48 h, and the cell viability was measured using MTT assay. Using EP extracts, a significant reduction of viable A549 cells was observed in a dose and time-dependent pattern. (Fig. 1). After 24 h incubation, the range of 400–900 ng/mL of EP extract were able to induce cell death, effectively (Fig. 1a). Treatment of A549 cells with 300 or 500 ng/mL of EP extract for 36 h, reduced cell viability about 20 and 30%, respectively (Fig. 1b). However, the treatment of A549 cells with 300 or 500 ng/mL of EP extract for 48 h, resulted in a decrease in cell viability about 30 and 50%, respectively (Fig. 1c). The respective calculated IC50 (the half-maximal inhibitory concentration) of EP extract following 24, 36- and 48-h incubation were 1.78, 1.19, and 0.51 μg/mL. Based on data, treatment of MRC-5 cells with 50–900 ng/mL of EP extract exhibited no significant reduction in the percentages of viable cells and the maximum reduction in the cell viability percentage was less than 10% (900 ng/mL treatment for 48 h) with the IC50 value of 8.24, 5.71 and 4.62 μg/mL after 24, 36- and 48-h incubation with EP (50–900 ng/mL). The SI values calculated for EP extract was 4.61, 4.79 and 9.05 for 24, 36 and 48 h incubation, respectively which indicated the high selectivity of EP for lung cancer cells versus lung normal cells (SI > 2 indicate high selectivity). To determine the possible involvement of CB2 receptor in EP extract-induced cell death, cells were pretreated with 10, 25, and 50 nM of AM630 for 30 min before treatment with 300 ng/mL of EP extract for 36 h. It was shown that pretreatment with AM630, reverses the cytotoxic effect of EP extract on A549 cells significantly as it is shown in Fig. 1d.

**CS extract induced cell death in A549 cells in a time and dose-dependent manner**

The impact of CS on the viability of human lung cancer cells was measured following treatment of cells with CS (50–900 ng/mL) for 24, 36, and 48 h. CS induced a significant reduction in the percentages of viable cells at the CS-concentrations of 400 to 900 ng/mL following 24 h incubation (Fig. 2a). It was observed that after 36 h incubation, the concentrations of 300 and 500 ng/mL of CS induced a decrease in the rate of viable cells, 15 and 25%, respectively (Fig. 2b). CS-concentrations of 300 and 500 ng/mL after 48 h incubation, induced a decrease in cell viability about 25 and 45%, respectively (Fig. 2c). The calculated IC50 of CS extract following 24, 36 and 48 h incubation was 2.28, 1.19, and 0.69 μg/mL, respectively. According to SI value calculation, our data
revealed the SI values of 3.49, 4.67 and 6.75 for 24, 36 and 48 h incubation of A549 or MRC-5 cells with CS extracts, respectively. Our data revealed high selectivity of CS extract for lung cancer cells versus lung normal cells (SI > 2 indicate high selectivity). The cytotoxic effect of CS extract (50–900 ng/mL) on MRC-5 cells after 24, 36 and 48 h incubation were not significant and the maximum decrease in the percentage of viable MRC-5 cells was less than 10%. The IC50 values of 7.97, 5.56 and 4.66 μg/mL after 24, 36- and 48-h incubation of MRC-5 cells with CS (50–900 ng/mL) were obtained. We hypothesized that the CS activity was modulated through CB receptors. To clarify the role of CB2 receptor, cells were pre-treated with AM630 and incubated with CS for 36 h. We found that reduced cell viability was induced by 300 ng/mL of CS, and was abrogated following blockade of the CB2 receptor by AM 630, at 25 and 50 ng/mL (Fig. 2d).

**EP and CS extracts induced apoptosis in human lung cancer cells**

To determine whether the cytotoxic effect of EP and CS on A549 cells was correlated with the induction of apoptosis, the annexin-V and PI double staining method was applied. Cells were exposed to EP extract at 100, 300, and 500 ng/mL for 36 h, then analyzed by flow cytometry. The annexin-V positive, PI negative cells were early apoptotic cells (Fig. 3a, and c, respectively). The
The percentage of early apoptotic cells increased with increasing concentrations of EP extract, compared to the un-treated A549 cells (Fig. 3b), but was reduced following pre-treatment with AM630 in cell cultures of EP 300 ng/mL ($P < 0.01$). Moreover, the treatment of A549 cells with 100, 300, and 500 ng/mL of CS extract for 36 h enhanced the rate of early apoptotic cells in a dose-dependent manner compared to the un-treated A549 cells (Fig. 4d). EP at 100 ng/mL increased the percentage of early apoptotic cells compared to the control cells, but the CS extract at 100 ng/mL failed to induce apoptosis following 36 h incubation. Pretreatment of A549 cells with AM630 reduced the percentage of apoptotic cells exposed to CS at 300 ng/mL ($P < 0.001$) (Fig. 3d).

EP and CS extracts induce cell cycle arrest in A549 cells
Accumulation of cells in the subG1 phase of the cell cycle, cell cycle arrest, is a hallmark of apoptosis. To study the effect of EP and CS extracts on the pattern of A549 cell cycle distribution, we incubated cells for 36 h with 100 and 300 ng/mL of EP and CS extracts, respectively, and analyzed by flow cytometry. The pattern of cell cycle distribution is shown in Fig. 4a. A549 cells accumulated in the subG1 phase following treatment with CS at 100 ($P < 0.05$) and 300 ng/mL ($P < 0.001$), compared to the untreated cells (Fig. 4b). In cell cultures exposed to CS at 300 ng/mL, pre-treatment with AM630 reduced the accumulation of cells in the subG1 phase ($P < 0.001$). Exposure to resulted in increased accumulation of cells in the subG1 phase which was significant at
ET 100 ($P < 0.01$) and 300 ng/mL ($P < 0.001$) compared to the control cells (Fig. 4c). The CB2 antagonist (AM630) attenuated the effect of EP at 300 ng/mL on the A549 cell cycle arrest ($P < 0.001$).

The elevation of ROS level following EP and CS-induced apoptosis

Elevation of cellular ROS level indicates cell stress and is accompanied with the induction of apoptosis. The cellular ROS level was measured in A549 cells following treatment with 100 and 300 ng/mL of EP and CS extract for 36 h and analyzed by flow cytometry (Fig. 5a). Data revealed an elevation in cellular ROS levels following 100 or 300 ng/mL of EP extract exposure, compared to control cells ($P < 0.001$) (Fig. 5b). AM630 pre-treatment attenuated this, i.e. the elevated ROS levels induced by EP at 300 ng/mL ($P < 0.001$) (Fig. 4b). CS at 300 ng/mL also induced elevation of cellular ROS levels ($P < 0.001$), compared to the untreated cells. This was abrogated with AM630 pre-treatment ($P < 0.001$) (Fig. 5c). Lower CS concentrations did not induce increased ROS levels in A549 cells (Fig. 5c).

The increased activity of caspase 3 toward EP and CS-elicited apoptosis in lung cancer cells

The possible involvement of caspase 3 as a mediator in apoptosis execution was assessed with increasing concentrations of EP and CS extracts. An increase in caspase 3 activity was detected with EP at 100 ($P < 0.05$) and 300 ng/mL ($P < 0.007$) (Fig. 6a), and CS extract at...
300 ng/mL ($P < 0.0073$). Lower concentrations of CS did not change caspase 3 activity, compared to the untreated cells (Fig. 6b). AM630 attenuated the increased caspase 3 activity induced by EP and CS extracts ($P < 0.05$), separately.

**Discussion**

Lung cancer is one of the deadliest human cancers and responsible for high rates of cancer related deaths worldwide. Effective therapeutic approaches is necessary due to its crippling effects on patient’s lives [8]. The advantages of using medicinal herbs as supplementary treatments along with the common anti-cancer treatments has received attention recently [24].

The high availability of these medicinal herbs with few side effects, and the benefit of having several treatment options make medicinal herbs useful as complementary drugs that can sensitize conventional medicines [16, 25]. *Echinacea purpurea* (EP) has attracted attention due to its wide biological effects to relieve cold symptoms, pain, seizure, wound healing, and chronic arthritis [26]. The plant derivatives have a reputation for their immune-modulating and anti-inflammatory effects since their administration enhances immune reactions and suppresses inflammation using different pathways [16, 27]. In vivo studies in mouse models showed that EP herb extract oil causes a decline in the concentration of IL–2, IL–6, and TNF-alpha and consequently suppresses inflammation [28]. EP herb extract increased the population of CD49+ and CD19+ lymphocytes in the mice spleen, increased the cytotoxic activity of natural killer (NK) cells and the level of interferon-alpha inhibited release of tumor necrosis factor-γ and IL1β and ultimately improved both innate and adaptive immune responses [29]. Additionally, its cytotoxicity and anti-tumorigenic features provided interesting evidence, but documentation of a direct inhibitory effect of EP derivatives on cancer cell growth is lacking. On the other hand, the remarkable anti-inflammatory capability of EP derivatives along with their immune-enhancing features, indicate an efficient alternative for suppressing tumor growth, stimulating the immune system, and creating a barrier against tumor cells. In support of this, this study applied an appropriate range of EP extract concentrations (50–900 ng/mL), at different time intervals, to clarify the possible cytotoxic effect of EP on lung cancer cells. Our data revealed that EP extract reduced the number of viable lung cancer cells in a time and dose-dependent manner. The cytotoxic effect was accompanied by the induction of apoptosis in the A549 cells. To the best of our knowledge, the relevance of EP extracts in the treatment of the lung cancer has not been investigated in previous studies, although daily administration of EP results in an increase in NK cells in the human bone marrow, generating sites and stimulation of NK cell activity, thereby improving the functionality of the immune system that may fight...
cancer cells [30]. EP flower extract and its major derivative, cichoric acid, induced apoptosis and inhibited tumor growth via inhibition of telomerase activity in human colon cancer cells, Caco-2 and HCT-116 cells [31]. Further, EP root extract induced apoptosis via DNA fragmentation and increased of caspase 3/7 activity in a dose and time dependent manner in human pancreatic cancer cells, MIA PaCa-2, and colon cancer cells, COLO320 [32]. Our data indicate that EP root extract induces accumulation of A549 cells in the subG1 phase.

Fig. 5 The effects of EP and CS extracts on cellular ROS level in human lung cancer cells. The A549 cells were treated with 100 and 300 ng/mL of EP and CS extracts, separately, for 36 h and subjected to ROS measurement. A represents the flow cytometry histograms indicating the untreated cells (a), cells treated with 100 ng/mL of EP (b), 300 ng/mL of EP (c), 300 ng/mL of EP + 50 ng/mL of AM630 (d), cells treated with 100 ng/mL of CS (e), 300 ng/mL of CS (f), and 300 ng/mL of CS + 50 ng/mL of AM630 (g). B represents the mean level of ROS following EP treatment. C represents the mean level of ROS following CS treatment. Data represent mean ± SD of three separate experiments. The statistical differences between treated and untreated groups were analyzed by ANOVA and are indicated by asterisks (*** = P < 0.001)
in a dose-dependent manner which accounts as a hallmark of apoptosis. Caspase activation is required for the execution of apoptotic cell death, but apoptosis may also be induced through a caspase-independent manner [33].

In accordance, the generation of cellular ROS, as inevitable byproducts of metabolism, is related to the induction of caspase activity and mediates apoptotic cell death [34]. Based on our data, exposure of A549 cells by increasing concentrations of EP root extract resulted in elevation of cellular ROS. EP extract administration caused an increase in the caspase 3 activity, indicating induction of caspase-dependent cell death following EP extract treatment. EP secondary metabolites such as alkamides are likely to be responsible for these pharmacological effects as they share structural similarity with cannabinoid components like anandamide [16].

Cannabinoids refer to a group of components with diverse biological effects that are mediated through activation of their specific G-protein-coupled receptors, namely, CB1 and CB2 [4, 35, 36]. Several cancer-related properties are attributed to the cannabinoids and their receptors, including tumor growth suppression, apoptosis induction, angiogenesis inhibition, and manipulation of cancer related signaling pathways [6, 7]. Cannabis derivatives and CB receptor activation has been reported to inhibit tumor growth through a wide range of mechanisms and in various types of tumors including non-small lung cancer [9], prostate cancer [5], breast cancer [7], mantle cell lymphoma [37], glioma [38], hepatocarcinoma [39] and colon cancer [40]. The present study revealed that the CS extract induced lung cancer cell death in a dose and time-dependent manner. The cytotoxic effect on A549 cells was accompanied by the induction of apoptosis and accumulation of cells in the subG1 phase of the cell cycle. In line with this finding, a cytotoxic effect of cannabidiol (CBD), the major derivative of Cannabis, was observed in the MDA-MB-231 breast cancer cell line and colon cancer cells [7, 31]. In the current study, the increased activity of caspase 3 and concurrent elevation of cellular ROS level following CS extract administration, indicate the possible involvement of ROS in the cannabis-induced caspase-dependent apoptosis in lung cancer cells. It was shown that, WIN-55 as a CB receptor agonist induced accumulation of cells in the sub G1 stage and overstimulation of caspase 3/7 in PC-3 prostate cancer cell lines [37]. Previously reported results were consistent with our observations, and showed an enhancement in the level of ROS in breast cancer cells which were induced by Cannabidiol (CBD) treatment [41]. Constituents of EP and CS herb plants can stimulate cannabinoid receptors and subsequently trigger the same pathways and immunologic reactions. Therefore, we assessed the possible role of the CB2 receptor in the apoptosis-induced effects induced by EP and CS extracts. M630, a CB2 antagonist, attenuated the rate of cell death, apoptosis, accumulation of cells in the sub G1 phase, ROS level, and caspase 3 activity, all induced by both EP and CS extracts in A549 cells. Based on these observations, the metabolites of EP (alkamides) and CS cannabinooids might mediate their effects through the CB2 receptor in A549 cells. In support of this, binding of alkamide to the CB2 receptor is required for the subsequent anti-inflammatory impact of alkamide [42]. Additionally, it was shown that the extracted
alkamides from EP root stimulate IL-10 and inhibit tumor necrosis factor (TNF), and ultimately carry out the immunomodulatory effects and suppress inflammation [43]. In conclusion, the pro-apoptotic impact of EP and CS extracts on lung cancer cells and the modulating involvement of the CB2 receptor was evaluated. The cannabinomimetic properties of EP root extract on the CB2 receptor might be attributed to the alkamides. These favorable effects of the EP root extract on cell death, apoptosis, cell cycle distribution, ROS level, and caspase activity elucidated consistency with the CS mentioned effects on the A549 cell line.

Conclusion
Based on the findings, it can be postulated that EP and CS extracts can inhibit lung cancer cell growth and induce apoptosis and should be considered as an alternative anti-cancer agent in lung cancer. However, more research is required to elucidate the detailed underlying molecular mechanism of action and the exact role of each derivative of these herbal extracts. Therefore, fractionation of both herbal extracts to purify active compounds and investigating the molecular pathways influenced by are highly recommended.

Abbreviations
ECS: Endocannabinoid system; CS: Cannabis sativa; EGFR: Epidermal growth factor receptor; FAK: Focal adhesion kinase; VCAM1: Vascular cell adhesion protein 1; MMP2: Matrix metalloproteinase 2; TAMs: Tumor-associated macrophages; EGF: Epidermal growth factor; EP: Echinacea purpurea; NKcs: Natural killer cells; PMN: Poly morpho-nuclear leukocytes; CB2: Cannabinoid receptor 2; GPCR: G-protein coupled receptor; NSCLC: Non-small cell lung cancer; ROS: Reactive oxygen species; DMEM: Dulbecco’s Modified Eagle Medium; EMEM: Eagle’s Minimum Essential Medium; MTI: 3-(4,5-dimethyl-2-yl)-2,5-diphenyltetrazolium bromide; DMSO: Dimethyl sulfoxide; PBS: Fetal bovine serum; Pen-Strep: Penicillin-streptomycin solution; DCStH-DA: 2’,7’-dichlorofluorescin diacetate; ANOVA: Non-parametric one-way analysis of variance; NK: Natural killer; IL: Interleukin; CBD: Cannabidiol; PI: Propidium iodide; DTT: Dithiothreitol; DEVD-pNA: DEVD conjugated to p-nitroaniline; Annexin-V-FITC: Annexin-V-fluorescein isothiocyanate

Acknowledgments
We sincerely thanks to Dr. Mahdi Vazirian for his scientific and valuable assistance.

Authors’ contributions
FH carried out the experiments and contributed in writing manuscript, AM provided plant extractions and contributed to data interpretation, VS contributed to study design, data analysis and writing manuscript, FKH contributed to experiment implementation and writing manuscript, MN contributed to data interpretation, BN contributed to study design, evaluated results and conclusions, gave scientific comments and approved the final manuscript. MTY designed and supervised the study, performed data analysis and wrote the manuscript. Notably, all authors have read and approved the manuscript.

Funding
This work was financially supported by Iran University of Medical Sciences (Grant Number: 97–3–4–12920). The funding body played no role in the design of the study, collection and analysis, also interpretation of data and in writing a manuscript.

Availability of data and materials
The data used to support the findings of this study are included within the article and any further information can be provided by corresponding author upon request.

Ethics approval and consent to participate
The project was ethically approved by the ethics committee of Vice president of research of Iran University of Medical Sciences with ethic committee code: IR.IUMS.FM.IREC.1398.061.

Consent for publication
Not applicable.

Competing interests
The authors declare that there is no conflict of interest.

Author details
1Department of Biochemistry, School of Medicine, Iran University of Medical Sciences, Tehran, Iran. 2Medicinal Plants Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. 3Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. 4Division of Pediatric and Adolescent Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway. 5Department of Pediatric and Adolescent Health, University of Botswana, Gaborone, Botswana.

Received: 11 August 2020 Accepted: 4 January 2021

Published online: 14 January 2021

References
1. Zou S, Kumar U. Cannabinoid receptors and the endocannabinoid system: signaling and function in the central nervous system. Int J Mol Sci. 2018; 19(3):833. https://doi.org/10.3390/ijms19030833.
2. Gertsch J, Raduner S, Altmann KH. New natural noncannabinoid ligands for cannabinoid type-2 (CB2) receptors. J Recept Signal Transduct Res. 2006; 265–6:705–30.
3. Gertsch J, Pertwee RG, Di Marco V. Phytocannabinoids beyond the Cannabis plant - do they exist? Br J Pharmacol. 2010;160(3):523–9.
4. Tahamant A, Samiepoor Y, Nayeri FS, Rahbarimanehs AA, Ijadi A, Rashidi-Nezhad A, Tavakoli-Yaraki M, Farahmand M, Bont L, Shokri F, et al. Effects of cannabinoid receptor type 2 in respiratory syncytial virus infection in human subjects and mice. Virulence. 2018;9(1):217–30.
5. Ruiz L, Miguel A, Diaz-Laviada I. Delta9-tetrahydrocannabinol induces apoptosis in human prostate PC-3 cells via a receptor-independent mechanism. FEBS Lett. 1999;458(3):400–4.
6. Nikan M, Nabavi SM, Manayi A. Ligands for cannabinoid receptors, promising anticancer agents. Life Sci. 2016;146:124–30.
7. Elbaz M, Nasser MW, Ravi J, Wani NA, Ahirwar DK, Zhao H, Oghumu S, Satoskar AR, Shilo K, Carson WE 3rd, et al. Modulation of the tumor microenvironment and inhibition of EGF/EGFR pathway: novel anti-tumor mechanisms of Cannabidiol in breast cancer. Mol Oncol. 2015;9(4):906–19.
8. Yang S, Zhang Z, Wang Q. Emerging therapies for small cell lung cancer. J Hematol Oncol. 2019;12(1):47.
9. Preet A, Qamri Z, Nasser MW, Prasad A, Shilo K, Zou S, Groopman JE, Ganju RK. Cannabinoid receptors, CB1 and CB2, as novel targets for inhibition of non-small cell lung cancer growth and metastasis. Cancer Prev Res (Phila). 2011;4(1):65–75.
10. Videkynski B, Gál P, Plátová M, Vidoz V, Solár P, Varinská L, Ivanová L, Mojžiš J. Anti-proliferative and anti-angiogenic effects of CB2R agonist (JWH-133) in non-small lung cancer cells (A549) and human umbilical vein endothelial cells: an in vitro investigation. Folia Biol. 2012;58(2):75–80.
11. Ravi J, Elbaz M, Wani NA, Nasser MW, Ganju RK. Cannabinoid receptor-2 agonist inhibits macrophage induced EMT in non-small cell lung cancer by downregulation of EGFR pathway. Mol Carcinog. 2016;55(12):2063–76.
12. Ngwa W, Kumar R, Moreau M, Dabney R, Herman A. Nanoparticle drones to target lung cancer with radiosensitizers and cannabinoids. Front Oncol. 2017;7:208.
13. Milan L, Mata M, Alacer J, Oliver M, Sancho-Tello M, Martín de Llano JJ, Camps C, Galbis J, Carretero J, Carda C. Cannabinoid receptor expression in non-small cell lung cancer. Effectiveness of tetrahydrocannabinol and cannabinoid inhibiting cell proliferation and epithelial-mesenchymal transition in vitro. PLoS One. 2020;15(2):e0228909.
14. McKeown KA. A review of the taxonomy of the genus Echinacea. Perspectives on new crops and new uses; 1999. p. 482–9.
15. Vimalanathan S, Schoop R, Suter A, Hudson J. Prevention of influenza virus induced bacterial superinfection by standardized Echinacea purpurea, via regulation of surface receptor expression in human bronchial epithelial cells. Virus Res. 2017;233:61–9.
16. Manayi A, Vazirani M, Saiednia S, Echinacea purpurea, pharmacology, phytchemistry and analysis methods. Pharmacogn Rev. 2015;9(17):63–72.
17. Fusco D, Liu X, Savage C, Taur Y, Xiao W, Kennelly E, Yuan J, Cassileth B, Salvatore M, Papanicolaou GA. Echinacea purpurea purpurea aerial extract alters course of influenza infection in mice. Vaccine. 2010;28(23):3956–62.
18. Razinia TG, Lopatina KA, Zueva AM, Guriev AM, Krylova SG, Amosova EN. Effect of Echinacea purpurea tincture and its polysaccharide complex on the efficacy of cytostatic therapy of transferred tumors. Eksp Klin Farmakol 2007, 70(3):33–35.
19. Woelkart K, Xu W, Pei Y, Makriyannis A, Picone RP, Bauer R. The anti-inflammatory effects of Echinacea purpurea flower extracts and cichoric acid on human colon cancer cell lines. J Ethnopharmacol. 2007;110(1):148–52.
20. Lin S, Khanolkar AD, Makriyannis A, Farrell P, Castanares A, Goutopoulos A, Qin C, Papahadjis D, Qin C, Papahadjis D, Makriyannis A. Novel analogues of arachidonylthanolamide (anandamide): affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability. J Med Chem. 1998;41(27):5533–61.
21. Gricht J, Schoop R, Kuznelz U, Suter A. Echinacea alkylamides modulate TNF-α gene expression via cannabinoid receptor CB2 and multiple signal transduction pathways. FEBS Lett. 2004;577(3):563–9.
22. Ross RA, Brockie HC, Stevenson LA, Murphy VL, Templeton F, Makriyannis A, Ross RA, Brockie HC, Stevenson LA, Murphy VL, Templeton F, Makriyannis A, Ross RA, Brockie HC, Stevenson LA, Murphy VL, Templeton F, Makriyannis A. Novel analogues of arachidonylthanolamide (anandamide): affinities for the CB1 and CB2 cannabinoid receptors of L550633, L579656, and AM630. Br J Pharmacol. 1999;126(3):665–72.
23. Machana S, Weerapreeyakul N, Barusrua S, Nonpunya A, Sritanidkulchai B, Thitmetharoct T. Cytotoxic and apoptotic effects of six herbal plants against the human hepatocarcinoma (hepG2) cell line. Chin Med. 2011;6(1):10.
24. Manayi A, Nabavi SM, Setzer WN, Jafari S. Piperine as a potential anti-cancer agent: a review on preclinical studies. Curr Med Chem. 2018;25(37):4918–25.
25. Barnes J, Anderson LA, Gibbons S, Phillipson JD. Echinacea species (Echinacea angustifolia (DC.) hell., Echinacea pallida (Nutt.) Nutt., Echinacea purpurea (L.) Moench): a review of their chemistry, pharmacology and clinical properties. J Pharm Pharmacol. 2005;57(8):929–54.
26. Barrett B. Medicinal properties of Echinacea: a critical review. Phytomedicine. 2003;10(1):166–86.
27. Grimw Müller H-H. A randomized controlled trial of the effect of fluid extract of Echinacea purpurea on the incidence and severity of colds and respiratory infections. Arzneimittelforschung. 1998;48(2):138–43.
28. Yu D, Yuan Y, Jiang L, Tai Y, Yang X, Hu F, Xie Z. Anti-inflammatory effects of essential oil in Echinacea purpurea L. Pak J Pharm Sci. 2013;26(2):403–8.
29. Zhai Z, Liu Y, Wu L, Serchena DS, Wurtele ES, Murphy PA, Kohut ML, Cunnick JE. Enhancement of innate and adaptive immune functions by multiple Echinacea species. J Med Food. 2007;10(3):423–34.
30. Miller SC. Echinacea: a miracle herb against aging and cancer? Evidence in vivo in mice. Evid Based Complement Alternat Med. 2005;2(3):309–14.
31. Tsai YL, Chiu CC, Y-Fu Chen J, Chan KC, Lin SD. Cytotoxic effects of Echinacea purpurea flower extracts and cichoric acid on human colon cancer cells through induction of apoptosis. J Ethnopharmacol. 2012;143(3):914–9.
32. Chicca A, Adinolfi B, Martinotti E, Fogli S, Breschi MC, Pelfati F, Benvenuti S, Nieri P. Cytotoxic effects of Echinacea root hexanic extracts on human cancer cell lines. J Ethnopharmacol. 2007;110(1):148–53.
33. Tait SW, Green DR. Caspase-independent cell death: leaving the set without the final cut. Oncogene. 2008;27(50):6452–61.
34. Choi K, Ryu SW, Song S, Choi H, Kang SW, Choi C. Caspase-dependent generation of reactive oxygen species in human astrocytoma cells contributes to resistance to TRAIL-mediated apoptosis. Cell Death Differ. 2010;17(5):833–45.
35. Patil KR, Goyal SN, Sharma C, Patil CR, Ojha S. Phytocannabinoids for Cancer therapeutics: recent updates and future prospects. Curr Med Chem. 2015;22(30):3472–501.
36. Tahamant A, Tavakoli-Yaraki M, Rygiei TP, Mohkhtari-Azad T, Salimi V. Effects of cannabinoids and their receptors on viral infections. J Med Virol. 2016;88(1):1–12.
37. Gustafsson K, Christensson B, Sander B, Flygare J. Cannabinoid receptor-mediated apoptosis induced by R(+)-methylamandamide and WIN55,212–2 is associated with ceramide accumulation and p38 activation in mantle cell lymphoma. Mol Pharmacol. 2006;70(5):1612–20.
38. Mezi F, Vaccari C, Ceruti S, Colombo A, Abbraccchio MP, Parolaro D. Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines. J Pharmacol Exp Ther. 2004;308(3):838–45.
39. Mukhopadhyay B, Schuebel K, Mukhopadhyay P, Cinar R, Godlewski G, Xiong K, Mackie L, Lizak M, Yuan Q, Goldman D, et al. Cannabinoid receptor 1 promotes hepatocellular carcinoma initiation and progression through multiple mechanisms. Hepatology. 2015;61(5):1615–26.
40. Gianschi F, Papucci L, Schiavone N, Lulli M, Magnelli L, Vinci MC, Messeini L, Manera C, Ronconi E, Romagnani P, et al. Cannabinoid receptor activation induces apoptosis through tumor necrosis factor alpha-mediated ceramide de novo synthesis in colon cancer cells. Clin Cancer Res. 2008;14(23):7691–700.
41. Ligresti A, Morillo AS, Starowicz K, Matias I, Pisanti S, De Petrocellis L, Iaezza C, Fortella G, Bifulco M, Di Marzo V. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J Pharmacol Exp Ther. 2006;318(3):175–87.
42. Gertsch J, Schoop R, Kuznelz U, Suter A. Echinacea alkylamides modulate TNF-alpha gene expression via cannabinoid receptor CB2 and multiple signal transduction pathways. FEBS Lett. 2004;577(3):563–9.
43. Chicca A, Raduner S, Pelfati F, Strompen T, Altmann KH, Schoop R, Gertsch J. Synergistic immunomopharmacological effects of N-alkylamides in Echinacea purpurea herbal extracts. Int Immunopharmacol. 2009;9(7–8):850–8.